| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
11beta-Hydroxysteroid dehydrogenase (11beta-HSD)
|
|---|---|
| ln Vitro |
Tetrahydro-11-dehydrocorticosterone is an inhibitor of 11beta-hydroxysteroid dehydrogenase (11beta-HSD), an enzyme that interconverts active and inactive glucocorticoids. As a steroid metabolite, it serves as a reference standard for investigating the intricate pathways of steroid hormone biosynthesis and metabolism. Its specific structure features an 11,20-dione, making it useful for probing the metabolic fate of corticosteroids and structure-activity relationships (SAR) of synthetic steroids. No specific IC50 value for 11beta-HSD inhibition is publicly available, but the compound is classified as an 11beta-HSD inhibitor. It is a reduced metabolite of corticosterone (tetrahydrogenated at C-3 and C-5 positions, with dehydrogenation at C-11).
|
| ln Vivo |
No specific in vivo data for Tetrahydro-11-dehydrocorticosterone. As an 11beta-HSD inhibitor and steroid metabolite, it has potential for in vivo modulation of glucocorticoid activity. Inhibition of 11beta-HSD type 1 (which converts inactive cortisone to active cortisol in humans, or 11-dehydrocorticosterone to corticosterone in rodents) can reduce local glucocorticoid levels in tissues such as liver, adipose tissue, and brain. Inhibition of 11beta-HSD type 2 (which converts active cortisol to inactive cortisone) can increase local glucocorticoid levels in the kidney and other mineralocorticoid target tissues. Tetrahydro-11-dehydrocorticosterone is primarily used as an analytical reference standard in steroid profiling studies rather than as a pharmacological tool for in vivo studies.
|
| Enzyme Assay |
Recombinant human 11beta-HSD1 or 11beta-HSD2 is expressed in insect cells or mammalian cells, and microsomal fractions are prepared. The 11beta-HSD activity assay measures the conversion of substrate to product using NADPH (for reductase activity) or NADP+ (for dehydrogenase activity) as cofactor. For 11beta-HSD1 reductase activity (inactive → active glucocorticoid): cortisone (in human) or 11-dehydrocorticosterone (in rodents) is used as substrate, and NADPH as cofactor. The product (cortisol or corticosterone) is quantified by HPLC or LC-MS/MS. For 11beta-HSD2 dehydrogenase activity (active → inactive glucocorticoid): cortisol (in human) or corticosterone (in rodents) is used as substrate, and NADP+ as cofactor. The product (cortisone or 11-dehydrocorticosterone) is quantified. Tetrahydro-11-dehydrocorticosterone is incubated with the enzyme and cofactor for 30-60 minutes at 37degC. The reaction is stopped by adding an organic solvent. Product formation is measured by LC-MS/MS. IC50 values are determined from dose-response curves. The compound is also used as a reference standard for LC-MS/MS calibration in steroid profiling.
|
| Cell Assay |
For cellular studies, primary human or rodent hepatocytes, adipocytes, or renal cells expressing 11beta-HSD can be used. Cells are cultured in appropriate media (e.g., DMEM with 10% FBS). For 11beta-HSD1 cellular assays, cells are treated with Tetrahydro-11-dehydrocorticosterone (0.1-100 uM) for 4-24 hours, then substrate (cortisone or 11-dehydrocorticosterone, 10-100 nM) is added. After 1-4 hours, the culture medium is collected, and the product (cortisol or corticosterone) is extracted and quantified by LC-MS/MS. Cellular 11beta-HSD enzyme activity is calculated as the amount of product formed per mg protein per hour. Cell viability is assessed by MTT or LDH assay. The compound can also be used as an internal standard in LC-MS/MS assays for steroid quantification. No specific cellular data for Tetrahydro-11-dehydrocorticosterone as an inhibitor is publicly available; these are generic protocols for 11beta-HSD inhibitors.
|
| Animal Protocol |
No published in vivo animal study for Tetrahydro-11-dehydrocorticosterone as a pharmacological agent. As a steroid metabolite and 11beta-HSD inhibitor, it has potential for in vivo studies of glucocorticoid metabolism. A typical protocol would involve administration of the compound to rodents (e.g., rats or mice) by intraperitoneal injection or oral gavage (1-50 mg/kg) formulated in a suitable vehicle (e.g., 10% DMSO + 90% corn oil). Plasma and tissue (liver, kidney, adipose, brain) samples are collected at various time points. 11beta-HSD activity in tissue homogenates is measured ex vivo using the biochemical assay described above. Endogenous glucocorticoid levels (corticosterone and 11-dehydrocorticosterone in rodents) are measured in plasma and tissues by LC-MS/MS. The ratio of active to inactive glucocorticoid is calculated as a pharmacodynamic measure of 11beta-HSD inhibition. However, Tetrahydro-11-dehydrocorticosterone is primarily used as an analytical reference standard, not as an in vivo tool compound. No specific in vivo data is publicly available.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data for Tetrahydro-11-dehydrocorticosterone. As a steroid (MW 348.48, LogP 2.746), the compound is lipophilic and would be expected to have high plasma protein binding, extensive tissue distribution, and moderate oral bioavailability. It is a metabolite of corticosterone, and its formation and clearance are part of normal steroid metabolism. The compound is likely metabolized further by conjugation (glucuronidation, sulfation) and excreted in urine and bile. Plasma half-life, Cmax, AUC, clearance, and volume of distribution have not been determined experimentally. Solubility: DMSO 25 mg/mL (71.74 mM). In vivo formulation: 10% DMSO + 40% PEG300 + 5% Tween80 + 45% saline (≥2.5 mg/mL, clear solution). Storage: powder at -20degC for 3 years.
|
| Toxicity/Toxicokinetics |
Tetrahydro-11-dehydrocorticosterone is a naturally occurring steroid metabolite and is not a toxic compound per se. As an endogenous metabolite present in the body, it is not expected to have significant acute toxicity. However, high doses of steroids can cause metabolic disturbances (e.g., glucose intolerance, lipid abnormalities) and immunosuppression. No specific toxicity data for Tetrahydro-11-dehydrocorticosterone is available, but as a reference standard, it is used at low concentrations in analytical assays. For research use, standard laboratory safety precautions (gloves, lab coat, eye protection) should be followed. Not for human therapeutic use.
|
| References | |
| Additional Infomation |
Tetrahydro-11-dehydrocorticosterone (CAS: 566-03-0) is a steroid metabolite and an inhibitor of 11beta-hydroxysteroid dehydrogenase (11beta-HSD), a key enzyme that interconverts active and inactive glucocorticoids. The compound is a reduced metabolite of corticosterone (tetrahydrogenated at C-3 and C-5 positions, with dehydrogenation at C-11). It serves as a critical intermediate and reference standard for investigating steroid hormone biosynthesis and metabolism pathways. Its specific structure featuring an 11,20-dione makes it useful for probing the metabolic fate of corticosteroids and structure-activity relationships (SAR) of synthetic steroids. Tetrahydro-11-dehydrocorticosterone is used as an analytical standard in LC-MS/MS steroid profiling and in studies of 11beta-HSD enzyme activity. Molecular formula: C21H32O4, molecular weight: 348.48. Appearance: white to off-white solid. Solubility: DMSO 25 mg/mL (71.74 mM). Storage: powder at -20degC for 3 years; in solvent at -80degC for 6 months. For research use only. Not approved for clinical use.
|
| Molecular Formula |
C21H32O4
|
|---|---|
| Molecular Weight |
348.48
|
| Exact Mass |
348.23
|
| CAS # |
566-03-0
|
| PubChem CID |
223684
|
| Appearance |
White to off-white solid powder
|
| Density |
1.175g/cm3
|
| Boiling Point |
508.5ºC at 760mmHg
|
| Flash Point |
275.4ºC
|
| Index of Refraction |
1.548
|
| LogP |
2.746
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
586
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CC12CCC(CC1CCC3C2C(=O)CC4(C3CCC4C(=O)CO)C)O
|
| InChi Key |
XWYBFXIUISNTQG-RHBMFIQRSA-N
|
| InChi Code |
InChI=1S/C21H32O4/c1-20-8-7-13(23)9-12(20)3-4-14-15-5-6-16(18(25)11-22)21(15,2)10-17(24)19(14)20/h12-16,19,22-23H,3-11H2,1-2H3/t12-,13-,14+,15+,16-,19-,20+,21+/m1/s1
|
| Chemical Name |
(3R,5R,8S,9S,10S,13S,14S,17S)-3-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-11-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8696 mL | 14.3480 mL | 28.6961 mL | |
| 5 mM | 0.5739 mL | 2.8696 mL | 5.7392 mL | |
| 10 mM | 0.2870 mL | 1.4348 mL | 2.8696 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
